Tech Company Financing Transactions
SemaThera Funding Round
SemaThera, operating out of Montreal QC, secured $2.6 million in investment from AmorChem and Senju Pharmaceutical.
Transaction Overview
Company Name
Announced On
3/28/2018
Transaction Type
Venture Equity
Amount
$2,600,000
Round
Undisclosed
Investors
AmorChem (Elizabeth Douville)
Senju Pharmaceutical (Mitsuyoshi Azuma)
Proceeds Purpose
The latest funding develop its lead candidate, ST-102, in preparation for a clinical trial application in diabetic macular edema (DME), an accumulation of fluid due to leaking blood vessels in the macula, which is part of the retina that controls most detailed vision abilities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Westmount Sq. 800
Montreal QC, H3Z 2P9
Canada
Montreal QC, H3Z 2P9
Canada
Phone
Undisclosed
Website
Email Address
Overview
SemaThera develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). SEMA 3A is a soluble protein that promotes vascular leakage and contributes to diabetes-related macular edema.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Garth Cumberlidge
Chief Operating Officer
Veronique Bougie
Chief Scientific Officer
Michael Sapieha
Browse more venture capital transactions:
Prev: 3/28/2018: Kenna Security venture capital transaction
Next: 3/28/2018: Pipefy venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs